# US 2026/0085303 A1 · Cell wall hydrolases targeting c. acnes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085303 A1
- Document ID: US20260085303A1
- Status: Published application
- Kind: A1
- Application number: 19/188,859
- Filed: 2025-04-24
- Published: 2026-03-26
- Earliest claimed: 2023-07-27
- Assignees: Topaz Biosciences, Inc.
- Applicants: Topaz Biosciences, Inc.
- Inventors: Jennifer SHOCK; Maritza MILLER; Oliver LIU; Teresa SHOCK
- Web page: https://patentgrep.com/patent/US20260085303A1

## CPC

- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 17/10: Anti-acne agents
- C07K 14/195: from bacteria
- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12Y 305/02: in cyclic amides (3.5.2)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C12Y 302/01017: Lysozyme (3.2.1.17)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to novel cell wall binding domains, enzymatically active domains, and chimeric cell wall hydrolases with anti-Cutibacterium acnes activity. The disclosure also relates to compositions comprising these, and uses thereof in the treatment of conditions associated with Cutibacterium acnes.

## Claims

### Claim 1

A chimeric cell wall hydrolase (CWH) comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 53 or 106, wherein the chimeric CWH exhibits lytic activity against Cutibacterium acnes.

### Claim 2 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH comprises SEQ ID NO: 53 or 106.

### Claim 3 (depends on 1)

The chimeric CWH of claim 1, wherein the CWH comprises:
a) an enzymatically active domain (EAD) comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 20 or 35; and/or
b) a cell wall binding domain (CBD) comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 42.

### Claim 4 (depends on 3)

The chimeric CWH of claim 3, wherein the EAD comprises the sequence of SEQ ID NO: 20 or 35.

### Claim 5 (depends on 3)

The chimeric CWH of claim 3, wherein the CBD comprises the sequence of SEQ ID NO: 42.

### Claim 6 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH exhibits lytic activity across a pH range of pH 4.2-8.0.

### Claim 7 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH exhibits lytic activity at a pH of about pH 5.5-6.5.

### Claim 8 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH retains at least 50% of its activity at 25° C. after being exposed to a temperature of up to 50° C. for 30 minutes.

### Claim 9 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH retains at least 50% of its activity at 25° C. after being exposed to a temperature of up to 75° C. for 30 minutes.

### Claim 10 (depends on 1)

The chimeric CWH of claim 1, wherein the chimeric CWH exhibits minimal or no lytic activity against Corynebacterium xerosis, Corynebacterium striatum, and/or Staphylococcus epidermidis.

### Claim 11 (depends on 1)

A topical formulation comprising the chimeric CWH according to claim 1.

### Claim 12 (depends on 11)

The formulation of claim 11, wherein the formulation comprises 5-20 g/mL of the chimeric CWH.

### Claim 13 (depends on 11)

The topical formulation of claim 11, wherein the formulation comprises a hydrogel, a spray, a cream, a lotion, a balm, an ointment, an aqueous formulation, or a patch.

### Claim 14 (depends on 13)

The topical formulation of claim 13, wherein the formulation comprises an aqueous formulation.

### Claim 15 (depends on 13)

The topical formulation of claim 13, wherein the patch comprises a microneedle patch or a colloidal patch.

### Claim 16 (depends on 13)

The topical formulation of claim 13, wherein the formulation comprises a spray.

### Claim 17 (depends on 13)

The topical formulation of claim 13, wherein the formulation comprises one or more of the following ingredients: a cellulose polymer, betaine, glycerin, panthenol, arginine, methionine, aloe vera, allantoin, and sodium hyaluronate.

### Claim 18 (depends on 17)

The topical formulation of claim 17, wherein the formulation comprises:
a) 0.1-20% w/v of a cellulose polymer;
b) 0.1-20% w/v betaine;
c) 0.01-2% w/v glycerin;
d) 0.1-10% w/v panthenol;
e) 0.01-2% w/v arginine;
f) 0.01-2% w/v methionine;
g) 0.1-20% w/v aloe vera; and/or
h) 0.01-5% w/v allantoin.

### Claim 19 (depends on 17)

The topical formulation of claim 17, wherein the formulation is a patch, and wherein the patch comprises:
a) 10-95% w/v sodium hyaluronate;
b) 10-95% w/v cellulose polymer;
c) 0.1-20% w/v glycerin;
d) 0.01-2% w/v arginine; and/or
e) 0.01-2% w/v methionine.

### Claim 20 (depends on 17)

The topical formulation of claim 17, wherein the cellulose polymer is selected from the group consisting of: hydroxyethyl cellulose, methylcellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, microcrystalline cellulose, ethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and cellulose acetate.

### Claim 21 (depends on 20)

The topical formulation of claim 20, wherein the formulation comprises hydroxypropyl methyl cellulose.

### Claim 22 (depends on 11)

The topical formulation of claim 11, wherein the formulation comprises betaine.

### Claim 23 (depends on 1)

A topical aqueous formulation comprising the chimeric CWH of claim 1 and comprising: salicylic acid, betaine, glycerin, panthenol, arginine, methionine, hydroxypropyl methylcellulose, and one or more of a solvent, an antioxidant, a buffer, a salt, and a preservative.

### Claim 24 (depends on 1)

A topical aqueous spray formulation comprising the chimeric CWH of claim 1 and comprising: betaine, aloe vera, allantoin, arginine, methionine, and one or more of a solvent, a buffer, a salt, and a preservative.

### Claim 25 (depends on 1)

A topical microneedle patch formulation comprising the chimeric CWH of claim 1 and comprising: sodium hyaluronate, cellulose polymer, glycerin, arginine, methionine, and one or more of a solvent, an antioxidant, a salt, and a preservative.

### Claim 26 (depends on 1)

A method of improving skin health comprising: applying the chimeric CWH of claim 1 to the skin.

### Claim 27 (depends on 1)

A method of treating acne vulgaris comprising: applying the chimeric CWH of claim 1 to the skin.

### Claim 28

A method of treating a skin condition associated with Cutibacterium sp. comprising: applying a chimeric cell wall hydrolase (CWH) to the skin, wherein the CWH comprises an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 53 or 106, wherein the chimeric CWH exhibits lytic activity against Cutibacterium sp.
